Trial Profile
A Retrospective Cohort Study Investigating Immune-Related Adverse Events (IRAE) of Checkpoint Inhibitors (CI) in Elderly Patients (PTS) with Advanced Melanoma (AMEL) in a Community Setting
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jun 2018
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 29 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.